Stromal cell diversity associated with immune evasion in human triple-negative breast cancer

基质细胞多样性与人类三阴性乳腺癌的免疫逃逸相关

阅读:15
作者:Sunny Z Wu,Daniel L Roden,Chenfei Wang,Holly Holliday,Kate Harvey,Aurélie S Cazet,Kendelle J Murphy,Brooke Pereira,Ghamdan Al-Eryani,Nenad Bartonicek,Rui Hou,James R Torpy,Simon Junankar,Chia-Ling Chan,Chuan En Lam,Mun N Hui,Laurence Gluch,Jane Beith,Andrew Parker,Elizabeth Robbins,Davendra Segara,Cindy Mak,Caroline Cooper ,Sanjay Warrier ,Alistair Forrest ,Joseph Powell ,Sandra O'Toole ,Thomas R Cox,Paul Timpson,Elgene Lim ,X Shirley Liu,Alexander Swarbrick

Abstract

The tumour stroma regulates nearly all stages of carcinogenesis. Stromal heterogeneity in human triple-negative breast cancers (TNBCs) remains poorly understood, limiting the development of stromal-targeted therapies. Single-cell RNA sequencing of five TNBCs revealed two cancer-associated fibroblast (CAF) and two perivascular-like (PVL) subpopulations. CAFs clustered into two states: the first with features of myofibroblasts and the second characterised by high expression of growth factors and immunomodulatory molecules. PVL cells clustered into two states consistent with a differentiated and immature phenotype. We showed that these stromal states have distinct morphologies, spatial relationships and functional properties in regulating the extracellular matrix. Using cell signalling predictions, we provide evidence that stromal-immune crosstalk acts via a diverse array of immunoregulatory molecules. Importantly, the investigation of gene signatures from inflammatory-CAFs and differentiated-PVL cells in independent TNBC patient cohorts revealed strong associations with cytotoxic T-cell dysfunction and exclusion, respectively. Such insights present promising candidates to further investigate for new therapeutic strategies in the treatment of TNBCs.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。